

Children's Mercy Kansas City

SHARE @ Children's Mercy

Posters

11-2022

Malignancy masquerading as steroid resistant hypereosinophilic syndrome

Sonya Parashar

Aarti Pandya

Follow this and additional works at: <https://scholarlyexchange.childrensmercy.org/posters>



Part of the Allergy and Immunology Commons

Hypereosinophilia with an anterior mediastinal mass (9153)

Sonya Parashar MD^{1,2}; Aarti Pandya MD^{1,2}

¹Children's Mercy Kansas City ²University of Missouri Kansas City

Background



- HES characterized by blood eosinophilia of 1500 EOS/mL with evidence of end-organ damage attributable to eosinophilia and no other cause.
- Rare in adults but even more rare in children
- Causes are divided between primary or clonal versus secondary or non-clonal including allergic disease, infections, drug reactions

Case presentation

- A 3-year-old male with questionable history of asthma was admitted for newly found anterior mediastinal mass and left pleural effusion.
- Past surgical history: none.
- Family history: no family history of eosinophilic disorders.
- Medications: albuterol, Flovent
- CT chest showed large left pleural effusion, possible abscess, small pericardial effusion, and concern for an anterior mediastinal mass due to mediastinal shift.

Case presentation continued

- The patient's absolute eosinophil count suddenly increased from 600 to 25,048 and remained elevated above 20,000.
- He developed recurrent eosinophilic pericardial effusions requiring multiple pericardiocentesis.
- Despite high dose steroids and inpatient use of mepolizumab, his hypereosinophilia persisted.
- After two inconclusive fine-needle aspirations of his mediastinal mass, the patient's family agreed to a sternotomy with removal of the mediastinal mass.
- Pathology eventually revealed myeloid sarcoma, a variant of acute myeloid leukemia.



Management

- High-dose steroids in 1 mg/kg/day in children and adults
- Patients with MHES and LHES are least responsive to corticosteroids
- For those with FIP1L1-PDGFR gene, imatinib is effective.
- Mepolizumab approved for 12 years old and greater with dose of 300 mg every 4 weeks particularly in patients who were FIP1L1-PDGFR negative.

Conclusions

- Since HES is so rare, mainly case reports are available.
- Steroid resistant HES should raise concern for underlying malignancy especially when eosinophils are above 20,000.

References

1. Rosenberg CE, Fulkerson PC, Williams PW. Diagnosis and management of pediatric hypereosinophilic syndrome. *J Allergy Clin Immunol Pract* 2022;10:1131-8.
2. Klion AD. How I treat hypereosinophilic syndrome. *Blood*. 2015;126(9):1069-1077.
3. Roufousse F, Kahn JE, Rothenberg ME, Wardlaw AJ, Klion AD, Kirby AV, Gilson MJ, etc. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. *J Allergy Clin Immunol* 2020;146:1397-405.
4. Parambil ASP, Prem S, Jack PM, Nair RA. Mediastinal mass with hypereosinophilia in a young boy- A diagnostic dilemma. *J Clin Diagn Res*. 2016 Jul;10(7):XD03-XD04. doi: 10.7860/JCDR/2016/19615.8202. Epub 2016 Jul 1.
5. Khatami A, Outhred AC, Britton PN, Huguon E, Lord DJE, Wong M, Charlton A, et al. Mediastinal mass in healthy adolescent at the Children's Hospital at Westmead, Australia. *Thorax* 2015;70:194-197. doi:10.1136/thoraxjnl-2014-205764.
6. Valent P. Mepolizumab in Hypereosinophilic Syndromes: Proposed Therapeutic Algorithm. *J Allergy Clin Immunol Pract* 2022;10:2375-7. 2213-2198.